DOI QR코드

DOI QR Code

Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery

  • Franzese, Ciro (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Franceschini, Davide (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Cozzi, Luca (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • D'Agostino, Giuseppe (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Comito, Tiziana (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • De Rose, Fiorenza (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Navarria, Pierina (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Mancosu, Pietro (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Tomatis, Stefano (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Fogliata, Antonella (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital) ;
  • Scorsetti, Marta (Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital)
  • Received : 2016.02.08
  • Accepted : 2016.04.08
  • Published : 2017.01.15

Abstract

Purpose The purpose of this study was to study the clinical outcome for patients with metastases of the adrenal gland treated with stereotactic body radiation therapy. Materials and Methods Forty-six patients were studied retrospectively. The dose prescription was 40 Gy in four fractions. Dosimetric analysis was performed using the dose volume histograms while clinical outcome was assessed using actuarial analysis with determination of the overall survival (OS) and local control (LC) rates. Results The planning objectives were met for all patients. With a median follow-up period of 7.6 months, at the last follow-up 42 patients (91.3%) were alive and four had died because of distant progression. The actuarial mean OS was $28.5{\pm}1.6months$, the median was not reached. One-year and 2-year OS were $87.6{\pm}6.1%$. None of the risk factors was significant in univariate analysis. Actuarial mean LC was $14.6{\pm}1.8months$ (95% confidence interval [CI], 11.0 to 18.2) and median LC was $14.5{\pm}2.0months$ (95% CI, 10.5 to 18.5). One-year and 2-year LC were $65.5{\pm}11.9%$ and $40.7{\pm}15.8%$, respectively. A mild profile of toxicity was observed in the cohort of patients. Forty patients (86.9%) showed no complication (grade 0); two patients reported asthenia, six patients (13.1%) reported either pain, nausea, or vomiting. Of these six patients, five patients (10.9%) were scored as grade 1 toxicity while one patient (2.2%) was scored as grade 2. Conclusion Stereotactic body radiation therapy treatment provided an adequate clinical response in the management of adrenal gland metastases.

References

  1. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf). 2002;56:95-101. https://doi.org/10.1046/j.0300-0664.2001.01435.x
  2. Wansaicheong G, Goh J. Adrenal metastases [Internet]. New York: Medsacape; 2016 [cited 2016 Mar 2]. Available from: http://www.emedicine.com/radio/TOPIC17.
  3. Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol. 2011;34:249-53. https://doi.org/10.1097/COC.0b013e3181dbb727
  4. Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058-62.
  5. Hellman S. Karnofsky Memorial Lecture: natural history of small breast cancers. J Clin Oncol. 1994;12:2229-34. https://doi.org/10.1200/JCO.1994.12.10.2229
  6. Luketich JD, Burt ME. Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg. 1996;62:1614-6. https://doi.org/10.1016/S0003-4975(96)00611-X
  7. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008;195:363-8. https://doi.org/10.1016/j.amjsurg.2007.12.018
  8. Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wangberg B. Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol. 2010;36:699-704. https://doi.org/10.1016/j.ejso.2010.04.002
  9. Kim SH, Brennan MF, Russo P, Burt ME, Coit DG. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer. 1998;82:389-94. https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<395::AID-CNCR20>3.0.CO;2-T
  10. Uberoi J, Munver R. Surgical management of metastases to the adrenal gland: open, laparoscopic, and ablative approaches. Curr Urol Rep. 2009;10:67-72. https://doi.org/10.1007/s11934-009-0012-0
  11. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in nonsmall-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008;26:1142-7. https://doi.org/10.1200/JCO.2007.14.2091
  12. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554-60. https://doi.org/10.1002/cncr.11084
  13. Hsieh MH, Lin ZY, Huang CJ, Shih MC, Chuang WL. Management of bilateral adrenal metastases from hepatocellular carcinoma: a case report. Kaohsiung J Med Sci. 2005;21:371-6. https://doi.org/10.1016/S1607-551X(09)70136-6
  14. Duh QY. Resecting isolated adrenal metastasis: why and how? Ann Surg Oncol. 2003;10:1138-9. https://doi.org/10.1245/ASO.2003.10.916
  15. Soffen EM, Solin LJ, Rubenstein JH, Hanks GE. Palliative radiotherapy for symptomatic adrenal metastases. Cancer. 1990;65:1318-20. https://doi.org/10.1002/1097-0142(19900315)65:6<1318::AID-CNCR2820650611>3.0.CO;2-H
  16. Short S, Chaturvedi A, Leslie MD. Palliation of symptomatic adrenal gland metastases by radiotherapy. Clin Oncol (R Coll Radiol). 1996;8:387-9. https://doi.org/10.1016/S0936-6555(96)80087-2
  17. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17:1100-7. https://doi.org/10.1634/theoncologist.2012-0092
  18. Scorsetti M, Mancosu P, Navarria P, Tozzi A, Castiglioni S, Clerici E, et al. Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol. 2011;187:238-44. https://doi.org/10.1007/s00066-011-2207-9
  19. Gunjur A, Duong C, Ball D, Siva S. Surgical and ablative therapies for the management of adrenal 'oligometastases': a systematic review. Cancer Treat Rev. 2014;40:838-46. https://doi.org/10.1016/j.ctrv.2014.04.001
  20. Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys. 2012;82:919-23. https://doi.org/10.1016/j.ijrobp.2010.11.060
  21. Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71-5. https://doi.org/10.1016/j.ijrobp.2008.10.079
  22. Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol. 2008;87:418-24. https://doi.org/10.1016/j.radonc.2008.03.013
  23. Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011;7:145-51. https://doi.org/10.2217/fon.10.165
  24. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187:245-51. https://doi.org/10.1007/s00066-011-2192-z
  25. Ahmed KA, Barney BM, Macdonald OK, Miller RC, Garces YI, Laack NN, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36:509-13. https://doi.org/10.1097/COC.0b013e3182569189
  26. Romero Arenas MA, Sui D, Grubbs EG, Lee JE, Perrier ND. Adrenal metastectomy is safe in selected patients. World J Surg. 2014;38:1336-42. https://doi.org/10.1007/s00268-014-2454-x